These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 20226332

  • 1. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
    Walkty A, Boyd DA, Gravel D, Hutchinson J, McGeer A, Moore D, Simor A, Suh K, Taylor G, Miller M, Mulvey MR, Canadian Nosocomial Infection Surveillance Program.
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):419-24. PubMed ID: 20226332
    [Abstract] [Full Text] [Related]

  • 2. Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea.
    Carman RJ, Genheimer CW, Rafii F, Park M, Hiltonsmith MF, Lyerly DM.
    Anaerobe; 2009 Dec; 15(6):244-8. PubMed ID: 19818865
    [Abstract] [Full Text] [Related]

  • 3. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
    Drudy D, Quinn T, O'Mahony R, Kyne L, O'Gaora P, Fanning S.
    J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
    [Abstract] [Full Text] [Related]

  • 4. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe.
    Spigaglia P, Barbanti F, Mastrantonio P, Brazier JS, Barbut F, Delmée M, Kuijper E, R Poxton I, On Behalf Of The European Study Group On Esgcd.
    J Med Microbiol; 2008 Jun; 57(Pt 6):784-789. PubMed ID: 18480338
    [Abstract] [Full Text] [Related]

  • 5. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H.
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [Abstract] [Full Text] [Related]

  • 6. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
    Spigaglia P, Barbanti F, Louie T, Barbut F, Mastrantonio P.
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2463-8. PubMed ID: 19364867
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.
    Ackermann G, Tang YJ, Kueper R, Heisig P, Rodloff AC, Silva J, Cohen SH.
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2348-53. PubMed ID: 11451695
    [Abstract] [Full Text] [Related]

  • 9. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes.
    Huang H, Wu S, Wang M, Zhang Y, Fang H, Palmgren AC, Weintraub A, Nord CE.
    Int J Antimicrob Agents; 2009 Apr; 33(4):339-42. PubMed ID: 19097757
    [Abstract] [Full Text] [Related]

  • 10. Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila.
    Almahmoud I, Kay E, Schneider D, Maurin M.
    J Antimicrob Chemother; 2009 Aug; 64(2):284-93. PubMed ID: 19474069
    [Abstract] [Full Text] [Related]

  • 11. Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India.
    Gaind R, Paglietti B, Murgia M, Dawar R, Uzzau S, Cappuccinelli P, Deb M, Aggarwal P, Rubino S.
    J Antimicrob Chemother; 2006 Dec; 58(6):1139-44. PubMed ID: 17071955
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains.
    Huang H, Weintraub A, Fang H, Wu S, Zhang Y, Nord CE.
    Anaerobe; 2010 Dec; 16(6):633-5. PubMed ID: 20849968
    [Abstract] [Full Text] [Related]

  • 13. Multidrug resistance in European Clostridium difficile clinical isolates.
    Spigaglia P, Barbanti F, Mastrantonio P, European Study Group on Clostridium difficile (ESGCD).
    J Antimicrob Chemother; 2011 Oct; 66(10):2227-34. PubMed ID: 21771851
    [Abstract] [Full Text] [Related]

  • 14. A double mutation in the gyrA gene is necessary to produce high levels of resistance to moxifloxacin in Campylobacter spp. clinical isolates.
    Ruiz J, Moreno A, Jimenez de Anta MT, Vila J.
    Int J Antimicrob Agents; 2005 Jun; 25(6):542-5. PubMed ID: 15876526
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
    Singh R, Ledesma KR, Chang KT, Hou JG, Prince RA, Tam VH.
    J Antimicrob Chemother; 2009 Sep; 64(3):556-62. PubMed ID: 19589810
    [Abstract] [Full Text] [Related]

  • 16. gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.
    Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC.
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3418-21. PubMed ID: 12384345
    [Abstract] [Full Text] [Related]

  • 17. Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.
    Hovde LB, Simonson DA, Rotschafer JC.
    Diagn Microbiol Infect Dis; 2008 Mar; 60(3):295-9. PubMed ID: 18053674
    [Abstract] [Full Text] [Related]

  • 18. Detection of gyrA and gyrB mutations in Clostridium difficile isolates by real-time PCR.
    Spigaglia P, Carattoli A, Barbanti F, Mastrantonio P.
    Mol Cell Probes; 2010 Apr; 24(2):61-7. PubMed ID: 19837154
    [Abstract] [Full Text] [Related]

  • 19. Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU.
    Liu YH, Kuo SC, Lee YT, Chang IC, Yang SP, Chen TL, Fung CP.
    J Microbiol Immunol Infect; 2012 Apr; 45(2):108-12. PubMed ID: 22153765
    [Abstract] [Full Text] [Related]

  • 20. In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden.
    Norén T, Alriksson I, Akerlund T, Burman LG, Unemo M.
    Clin Microbiol Infect; 2010 Aug; 16(8):1104-10. PubMed ID: 19732094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.